1月23日——OKYO Pharma Limited宣布，美国食品药品监督管理局（FDA）已批准其药物Urcosimod（0.05%）用于神经性角膜疼痛（NCP）的同情用药。
该公司计划于今年启动一项涉及120名患者的临床研究，旨在评估Urcosimod治疗神经性角膜疼痛的疗效与安全性。
1月23日——OKYO Pharma Limited宣布，美国食品药品监督管理局（FDA）已批准其药物Urcosimod（0.05%）用于神经性角膜疼痛（NCP）的同情用药。
该公司计划于今年启动一项涉及120名患者的临床研究，旨在评估Urcosimod治疗神经性角膜疼痛的疗效与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.